ASTRANA HEALTH INC (ASTH)
US03763A2078 - Common Stock
We assign a fundamental rating of 5 out of 10 to ASTH. ASTH was compared to 107 industry peers in the Health Care Providers & Services industry. ASTH has only an average score on both its financial health and profitability. ASTH shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year ASTH was profitable.
ASTH had a positive operating cash flow in the past year.
Of the past 5 years ASTH 4 years were profitable.
Of the past 5 years ASTH 4 years had a positive operating cash flow.
1.2 Ratios
ASTH's Return On Assets of 4.86% is fine compared to the rest of the industry. ASTH outperforms 80.00% of its industry peers.
ASTH has a better Return On Equity (8.86%) than 74.29% of its industry peers.
ASTH has a Return On Invested Capital of 5.11%. This is in the better half of the industry: ASTH outperforms 60.95% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ASTH is in line with the industry average of 8.15%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.86% | ||
| ROE | 8.86% | ||
| ROIC | 5.11% |
ROA(3y)6.42%
ROA(5y)N/A
ROE(3y)11.12%
ROE(5y)N/A
ROIC(3y)7.41%
ROIC(5y)N/A
1.3 Margins
ASTH has a better Profit Margin (3.63%) than 75.24% of its industry peers.
ASTH's Profit Margin has declined in the last couple of years.
ASTH's Operating Margin of 4.92% is fine compared to the rest of the industry. ASTH outperforms 62.86% of its industry peers.
ASTH's Operating Margin has declined in the last couple of years.
ASTH has a Gross Margin of 15.09%. This is in the lower half of the industry: ASTH underperforms 71.43% of its industry peers.
In the last couple of years the Gross Margin of ASTH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.92% | ||
| PM (TTM) | 3.63% | ||
| GM | 15.09% |
OM growth 3Y-19.54%
OM growth 5YN/A
PM growth 3Y-7.38%
PM growth 5YN/A
GM growth 3Y-10.38%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ASTH is destroying value.
The number of shares outstanding for ASTH has been increased compared to 1 year ago.
ASTH has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.01 indicates that ASTH is not in any danger for bankruptcy at the moment.
ASTH's Altman-Z score of 4.01 is fine compared to the rest of the industry. ASTH outperforms 80.00% of its industry peers.
ASTH has a debt to FCF ratio of 6.29. This is a slightly negative value and a sign of low solvency as ASTH would need 6.29 years to pay back of all of its debts.
ASTH has a Debt to FCF ratio of 6.29. This is in the better half of the industry: ASTH outperforms 71.43% of its industry peers.
ASTH has a Debt/Equity ratio of 0.60. This is a neutral value indicating ASTH is somewhat dependend on debt financing.
ASTH has a Debt to Equity ratio (0.60) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 6.29 | ||
| Altman-Z | 4.01 |
ROIC/WACC0.6
WACC8.53%
2.3 Liquidity
A Current Ratio of 1.91 indicates that ASTH should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.91, ASTH is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
ASTH has a Quick Ratio of 1.91. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ASTH (1.91) is better than 73.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.91 |
3. Growth
3.1 Past
ASTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.00%, which is quite impressive.
Measured over the past years, ASTH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.55% on average per year.
Looking at the last year, ASTH shows a very strong growth in Revenue. The Revenue has grown by 21.19%.
ASTH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 26.37% yearly.
EPS 1Y (TTM)30%
EPS 3Y8.55%
EPS 5YN/A
EPS Q2Q%-29.79%
Revenue 1Y (TTM)21.19%
Revenue growth 3Y26.37%
Revenue growth 5YN/A
Sales Q2Q%37.49%
3.2 Future
Based on estimates for the next years, ASTH will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.23% on average per year.
ASTH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.86% yearly.
EPS Next Y-10.57%
EPS Next 2Y6.51%
EPS Next 3Y15.06%
EPS Next 5Y18.23%
Revenue Next Year44.51%
Revenue Next 2Y38.54%
Revenue Next 3Y32.79%
Revenue Next 5Y12.86%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 24.75, the valuation of ASTH can be described as rather expensive.
Based on the Price/Earnings ratio, ASTH is valued a bit cheaper than the industry average as 62.86% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ASTH to the average of the S&P500 Index (27.41), we can say ASTH is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 21.49, the valuation of ASTH can be described as rather expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as ASTH.
ASTH's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.69.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.75 | ||
| Fwd PE | 21.49 |
4.2 Price Multiples
ASTH's Enterprise Value to EBITDA ratio is in line with the industry average.
Based on the Price/Free Cash Flow ratio, ASTH is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.9 | ||
| EV/EBITDA | 17.33 |
4.3 Compensation for Growth
A more expensive valuation may be justified as ASTH's earnings are expected to grow with 15.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.51%
EPS Next 3Y15.06%
5. Dividend
5.1 Amount
ASTH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ASTRANA HEALTH INC
NASDAQ:ASTH (1/3/2025, 8:20:47 PM)
After market: 32.18 0 (0%)32.18
-0.02 (-0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners48.66%
Inst Owner ChangeN/A
Ins Owners9.42%
Ins Owner Change17.12%
Market Cap1.81B
Analysts85.56
Price Target65.79 (104.44%)
Short Float %3.79%
Short Ratio5.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP99.14%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.15%
Min EPS beat(2)0.55%
Max EPS beat(2)1.74%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)0.55%
Max EPS beat(4)71.85%
EPS beat(8)7
Avg EPS beat(8)19.76%
EPS beat(12)10
Avg EPS beat(12)21.43%
EPS beat(16)14
Avg EPS beat(16)29.22%
Revenue beat(2)2
Avg Revenue beat(2)4.83%
Min Revenue beat(2)1.5%
Max Revenue beat(2)8.16%
Revenue beat(4)3
Avg Revenue beat(4)1.73%
Min Revenue beat(4)-4.21%
Max Revenue beat(4)8.16%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.6%
PT rev (3m)10.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-36.78%
EPS NY rev (1m)-0.92%
EPS NY rev (3m)-9.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.71%
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)9.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.75 | ||
| Fwd PE | 21.49 | ||
| P/S | 1.05 | ||
| P/FCF | 25.9 | ||
| P/OCF | 21.96 | ||
| P/B | 2.57 | ||
| P/tB | 9.74 | ||
| EV/EBITDA | 17.33 |
EPS(TTM)1.3
EY4.04%
EPS(NY)1.5
Fwd EY4.65%
FCF(TTM)1.24
FCFY3.86%
OCF(TTM)1.47
OCFY4.55%
SpS30.62
BVpS12.53
TBVpS3.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.86% | ||
| ROE | 8.86% | ||
| ROCE | 8.72% | ||
| ROIC | 5.11% | ||
| ROICexc | 7.98% | ||
| ROICexgc | 48.09% | ||
| OM | 4.92% | ||
| PM (TTM) | 3.63% | ||
| GM | 15.09% | ||
| FCFM | 4.06% |
ROA(3y)6.42%
ROA(5y)N/A
ROE(3y)11.12%
ROE(5y)N/A
ROIC(3y)7.41%
ROIC(5y)N/A
ROICexc(3y)12.09%
ROICexc(5y)N/A
ROICexgc(3y)52.51%
ROICexgc(5y)N/A
ROCE(3y)12.64%
ROCE(5y)N/A
ROICexcg growth 3Y21.3%
ROICexcg growth 5YN/A
ROICexc growth 3Y3.5%
ROICexc growth 5YN/A
OM growth 3Y-19.54%
OM growth 5YN/A
PM growth 3Y-7.38%
PM growth 5YN/A
GM growth 3Y-10.38%
GM growth 5YN/A
F-Score5
Asset Turnover1.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 6.29 | ||
| Debt/EBITDA | 3.87 | ||
| Cap/Depr | 50.83% | ||
| Cap/Sales | 0.73% | ||
| Interest Coverage | 3.05 | ||
| Cash Conversion | 75.32% | ||
| Profit Quality | 111.9% | ||
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.91 | ||
| Altman-Z | 4.01 |
F-Score5
WACC8.53%
ROIC/WACC0.6
Cap/Depr(3y)133.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.18%
Cap/Sales(5y)N/A
Profit Quality(3y)90.19%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3Y8.55%
EPS 5YN/A
EPS Q2Q%-29.79%
EPS Next Y-10.57%
EPS Next 2Y6.51%
EPS Next 3Y15.06%
EPS Next 5Y18.23%
Revenue 1Y (TTM)21.19%
Revenue growth 3Y26.37%
Revenue growth 5YN/A
Sales Q2Q%37.49%
Revenue Next Year44.51%
Revenue Next 2Y38.54%
Revenue Next 3Y32.79%
Revenue Next 5Y12.86%
EBIT growth 1Y-18.85%
EBIT growth 3Y1.67%
EBIT growth 5YN/A
EBIT Next Year63.51%
EBIT Next 3Y35.99%
EBIT Next 5Y23.82%
FCF growth 1Y-32.93%
FCF growth 3Y-4.09%
FCF growth 5YN/A
OCF growth 1Y-16.93%
OCF growth 3Y13.91%
OCF growth 5YN/A